The EphA2 receptor tyrosine kinase is frequently overexpressed in invasive breast cancer cells. Moreover, these malignant cells have unstable cell-cell contacts, which preclude EphA2 from interacting with its ligand, EphrinA1, which is anchored to the membrane of adjacent cells. This defect is important because ligand binding causes EphA2 to transmit signals that negatively regulate tumor cell growth and survival, whereas the absence of ligand binding favors these same behaviors. In our present study, human adenoviral type 5 (HAd) vectors were engineered to express secreted-forms of EphrinA1. These vectors were used to infect MDA-MB-231 human breast cancer cells, or MCF-10A human breast epithelial cells providing matched controls. Infection with HAd-EphrinA1-Fc (HAd vector expressing extracellular domain of human EphrinA1 attached to Fc portion of human IgG 1 heavy chain) caused increased EphA2 activation and turnover and consequently decreased tumor cell viability in soft agar assays. Consistent with this observation, infection of MDA-MB-231 cells with HAd-EphrinA1-Fc prevented tumor formation in xenograft models. Furthermore, therapeutic modeling via intratumoral inoculation revealed that HAd-EphrinA1-Fc significantly inhibited subsequent tumor growth as compared to matched controls. These results suggest that targeting of EphA2 with adenoviral vectors may have therapeutic value.
C hanges in the expression or function of receptor tyrosine kinases have been linked to many types of cancers, most notably breast cancer. 1 Tyrosine kinases transmit powerful signals that are essential for the growth, survival and invasiveness of aggressive cancer cells. For instance, the EphA2 receptor tyrosine kinase is overexpressed in many highly aggressive breast cancers. 2 High levels of EphA2 have been documented in many different cancers [2] [3] [4] [5] [6] and this overexpression has been attributed to many different transcriptional and posttranslational modifications that frequently arise in cancer. For example, EphA2 expression is governed in part by p53 and Ras, both of which are frequently altered in cancer. 7, 8 These changes are important because high levels of EphA2 are sufficient to promote a tumorigenic phenotype, 2 which clearly demonstrate a role for EphA2 overexpression in cancer.
Much recent evidence has shown that EphA2 functions very differently in normal versus malignant cells. 9, 10 For example, EphA2 may function in normal cells as a negative regulator of cell growth and migration to mediate contact inhibition at high cell density. These outcomes appear to arise from the fact that EphA2 binds a ligand, known as EphrinA1, [11] [12] [13] which is anchored to the membrane of adjacent cells. The biochemical consequences of ligand binding include EphA2 autophosphorylation, [11] [12] [13] which mediates active signaling that decreases extracellular matrix (ECM) attachment and importantly, increases EphA2 turnover. Consequently, normal epithelial cells generally have low levels of EphA2 protein, which is itself tyrosine phosphorylated. However, tumor cells generally have unstable cell-cell contacts and this decreases EphA2-EphrinA1 binding.
14 Consequently, the EphA2 in malignant cells is not phosphorylated, which alters the subcellular localization and function of EphA2 in a manner that favors tumor cell growth and survival. 2 Compounding this, decreased ligand-mediated turnover causes EphA2 to accumulate at the cell surface. However, restoration of EphA2 stimulation can be achieved using artificial ligands 15 and monoclonal antibodies 16 and these treatments negatively regulate tumor cell growth and survival.
Human adenovirus (HAd)-based vectors have been the focus of considerable interest in the last few years, based on their potential application as delivery vehicles for human gene therapy. [17] [18] [19] [20] The results of animal studies and clinical trials in humans for cancer therapy have further increased interest in adenoviral-based therapy. [21] [22] [23] [24] [25] [26] Based on the differential ligand binding that EphA2 demonstrates in normal versus malignant cells, we describe herein the engineering of HAd type 5 (HAd5) vectors that express secreted forms of EphrinA1 and show that these vectors can negatively regulate tumor cell growth in vitro and in vivo.
Results

Generation of HAd5 vector containing ephrinA1-Fc or ephrinA1-Sc
Two variants of EphrinA1 constructs: (i) a secretory-form consisting only of extracellular domain (lacking native GPI-anchorage) genetically conjugated to the Fc portion of IgG 1 (EphrinA1-Fc), and (ii) the extracellular domain of EphrinA1 lacking GPI-anchorage and without Fc portion of IgG 1 (EphrinA1-Sc) were used to generate HAd-EphrinA1-Fc and HAd-EphrinA1-Sc, respectively (Fig 1) . These vectors were generated using Cre recombinase-mediated site-specific recombination. 27 Similarly, an empty vector (HAd-DE1E3) was also generated to serve as a negative control. These vectors were purified by cesium chloride density-gradient centrifugation and DNA was isolated from purified virions. To determine whether HAd vectors contained the correct insert, DNA samples were digested with HindIII, XhoI, or KpnI and the resultant fragments were separated by agarose gel electrophoresis. HAd-EphrinA1-Fc, HAd-EphrinA1-Sc, and HAd-DE1E3 produced the expected restriction patterns suggesting the authenticity of these vectors (data not shown). For further characterization of these vectors, total cellular RNA was isolated from vector-infected cells and analyzed by Northern blot using an EphrinA1-specific radiolabeled probe. The major bands showing hybridization with the probe were approximately 1.8 and 1.4 kb in RNA samples isolated from HAd-EphrinA1-Fcor HAd-EphrinA1-Sc-infected cells, respectively suggesting that EphrinA1-Fc and EphrinA1-Sc were expressed in infected cells (Fig 2) . The appearance of EphrinA1-Sc-like signal in both the HAd-DE1E3 and HAd-EphrinA1-Fc lanes may represent endogenous EphrinA1.
EphrinA1 expression in HAd vector-infected cells
To detect the Fc portion of IgG 1 attached with EphrinA1, 293 or MDBK cells were mock-infected or infected either with HAd-EphrinA1-Sc, HAd-EphrinA1-Fc, or HAd-DE1E3 for 24 or 48 hours. Cell extracts and supernatants were analyzed by Western blot analyses to detect the Fc portion of EphrinA1-Fc. In HAd-EphrinA1-Fc-infected 293 cell lysates and supernatants, EphrinA1-Fc was detected at both 24 and 48 hours time points (Fig 3a) . On the other hand, in MDBK cells (without E1 complementation), most EphrinA1-Fc-was restricted to supernatants. EphrinA1-Fc expressed in HAd-EphrinA1-Fc-infected cells migrated at the level similar to EphrinA1-Fc purified from 293 cells stably expressing EphrinA1-Fc. No specific bands were detected in cell lysates or supernatants of 293 or MDBK mock-infected or infected with HAd-EphrinA1-Sc or HAd-DE1E3. These results suggest that HAd-EphrinA1-Fc can induce efficient expression and secretion of EphrinA1-Fc.
To confirm the expression of EphrinA1 by vectors containing EphrinA1, 293 cells were mock-infected or infected with HAd-EphrinA1-Sc, HAd-EphrinA1-Fc, or Figure 1 Diagrammatic representation of the structure of HAd5 vectors. Three HAd vectors: (1) HAd-EphrinA1-Fc (HAd vector containing EphrinA1-Fc), (2) HAd-EphrinA1-Sc (HAd vector containing EphrinA1-Sc), and (3) HAd-DE1E3 (HAd vector having the m-CMV promoter, Poly A, and loxP site) were generated by Cre recombinase-mediated site-specific recombination. ITR, inverted terminal repeat; CMV, human cytomegalovirus immediate early promoter; m-CMV, mouse cytomegalovirus immediate early promoter; Poly A, simian virus 40 polyadenylation site, Lox P, loxP site for site-specific recombination by Cre recombinase; DE1, deletion in early region 1 (E1); DE3, deletion in early region 3 (E3). HAd-DE1E3 and harvested at 24 and 48 hours postinfection. Supernatants and cell extracts were analyzed for EphrinA1 expression by Western blot analyses. In HAdEphrinA1-Fc infected cells, EphrinA1-Fc (approximately 65 kDa) expression was observed both in cell extracts and supernatants at 24 and 48 hours postinfection (Fig 3b) , whereas in HAd-EphrinA1-Sc infected cells, EphrinA1-Sc (approximately 25 kDa) expression was detected in the cell extract and the supernatant at 48 hours postinfection. These results confirmed expression of EphrinA1-Fc or EphrinA1-Sc by HAd-EphrinA1-Fc or HAd-EphrinA1-Sc, respectively.
EphA2 expression and phosphorylation in vector-infected cells
Transduction efficiencies of 293, MDA-MB-231 and MCF-10A cell lines with a HAd5 vector were 91, 82 and 63% respectively as determined using a HAd5 vector (HAd-GFP) expressing green fluorescent protein (GFP) as a reporter 28 suggesting that HAd5 vectors will efficiently transduce both MDA-MB-231 and MCF-10A cells. To find out if EphrinA1 expression by HAd vectors might alter EphA2 expression or function, MDA-MB-231 or MCF-10A cells were mock-infected or infected either with HAd-EphrinA1-Sc, HAd-EphrinA1-Fc, or HAd-DE1E3. Cell lysates were collected at various times postinfection and subjected to Western blot analyses with antibodies specific for EphA2, E-cadherin, or b-catenin. Immunoprecipitated products obtained with an anti-EphA2 antibody were also subjected to Western blot analysis using an anti-phosphotyrosine (P-Tyr) antibody (Fig 4) . EphA2 became phosphorylated efficiently within 12 hours in HAd-EphrinA1-Fc cells and this persisted for at least 24 hours. Notably, the levels of EphA2 phosphotyrosine content decreased by 36 hours and further analyses of whole cell lysates indicated that this outcome was the result of increased EphA2 turnover. EphA2 activation and degradation was also observed in HAd-EphrinA1-Sc-infected cells though the timing and efficiency of these responses were considerably lower than results with cells infected with HAd-EphrinA1-Fc.
The majority of EphrinA1 and EphA2 in mock-or HAd-DE1E3-infected MDA-MB-231 cells was present as intracellular aggregates as detected by immunofluorescence assay (IFA). Whereas in HAd-EphrinA1-Sc, or HAd-EphrinA1-Fc-infected breast cancer cells, EphrinA1 and its derivatives were diffusely distributed in the cytoplasm and also on the cell surface (data not shown). However, in HAd-EphrinA1-Fc-infected cells, the intensity of EphA2 immunoreactivity in IFA was drastically reduced (data not shown), which was consistent with the increased EphA2 turnover observed by Western blot analyses (Fig 4) . As expected, MCF-10A cells expressed moderate levels of EphrinA1 and distributed on the cell surface and none of the experimental conditions altered EphrinA1 or EphA2 distribution significantly in IFA (data not shown).
It has been demonstrated that expression of E-cadherin in MDA-MB-231 cells improved EphA2 activation. 29 We wanted to know whether activation of EphA2 enhances expression of E-cadherin in MDA-MB-231 cells. The levels of E-cadherin expression in breast cancer cells were below the detection level at all times, irrespective of the type of vector treatment (Fig 4) suggesting that EphA2 activation does not restore E-cadherin expression to normal levels. No visible change in E-cadherin expression was observed in MCF-10A with any of the HAd vector infection (Fig 4) . Cancer cells can survive and grow in semisolid matrices (e.g. soft agar), and this behavior distinguishes malignant from nontransformed cells. For many cancer cell lines, soft agar colonization relates to metastatic potential. 30 To find out if HAd vectors that express EphrinA1 might alter this phenotype, MDA-MB-231 or MCF-10A cells were mock-infected or infected either with HAd-EphrinA1-Sc, HAd-EphrinA1-Fc, or HAd-DE1E3 prior to suspension in semisolid agar. Consistent with previous findings, MCF-10A cells could not colonize whereas MDA-MB-231 cells efficiently colonized soft agar (25675, 257766 colonies by mock and HAd-DE1E3 controls, respectively) (Fig 5a) . Notably, HAd-EphrinA1-Fc infection dramatically reduced colony formation. HAd-EphrinA1-Sc infection did not inhibit colony formation as efficiently as HAd-EphrinA1-Fc, which was consistent with its decreased biochemical activity (Fig 4) .
We then related the inhibitory effects of HAdEphrinA1-Fc with cell viability and observed a steady decline in MDA-MB-231 cells viability over time, with 1170.2% viability at the 96-hour time point (Fig 5b) . The decline observed using HAd-EphrinA1-Sc was less dramatic, but this construct was also able to significantly (Po.05) inhibit MDA-MB-231 cell viability. These results suggest that the decreased soft agar colonization of HAdEphrinA1-Fc represents active tumor cell killing.
Inhibition in tumorigenic potential of breast cancer cells-infected with HAd-EphrinA1-Fc in nude mice
To evaluate the potential effect of targeted EphrinA1-Fc expression in vivo, vector-infected MDA-MB-231 cells were evaluated for their tumorigenic potential in nude mice. In animals inoculated with mock-or HAd-DE1E3-infected cells, palpable tumors were apparent within 2 weeks postimplantation and steadily increased thereafter (Fig 6a) . Infection with control HAd-DE1E3-infected cells did not significantly alter tumor volume relative to mockinfected cells. In dramatic contrast, MDA-MB-231 cells that had been infected with HAd-EphrinA1-Fc failed to establish tumors in nude mice (Fig 6a) . These animals remained tumor-free throughout the study (48 days) and postmortem analysis did not reveal the presence of tumors at the site of inoculation (data not shown).
Inhibition in growth of MDA-MB-231-induced tumors by intratumoral inoculation with HAd-ephrinA1-Fc
Although the results above were encouraging, we considered that preventative studies using cells that had been treated with HAd-EphrinA1-Fc prior to implantation did not impart a high degree of physiological relevance. To evaluate these constructs within a more therapeutically relevant setting, our next line of investigation utilized animals bearing established tumors. Once the tumors reached a volume of 50-100 mm 3 , the mice were treated intratumoral (i.t.) with either PBS, HAd-DE1E3, 
Tumorigenicity of
or HAd-EphrinA1-Fc. Tumor volume was then tracked over time. Whereas the vector control (HAd-DE1E3) did not differ significantly from mock controls (Fig 6b) , HAdEphrinA1-Fc treatment decreased tumor growth. The decrease in tumor growth was durable, lasting at least 11 days following treatment.
Discussion
The major finding of our present study is that targeting of malignant cells with adenoviral vector expressing EphrinA1-Fc is sufficient to decrease tumorigenic potential in vitro and in vivo. We also relate the efficacy of this targeting strategy to EphA2 activation and degradation. These findings have implications for many different cancers that overexpress EphA2 including metastatic melanoma, breast, prostate, colon, lung, ovarian, and esophageal cancers.
2,4-6 Moreover, EphA2 in these cells is not tyrosine phosphorylated and thus accumulates at the cell surface. Importantly, overexpression of EphA2 observed in these cells occurs without a change in the binding motif for its ligand, EphrinA1. Rather, the defect appears to reside at the level of decreased cell-cell stability. In particular, stable EphA2-EphrinA1 binding requires the proper expression and functioning of E-cadherin. Consistent with this, the defect in EphA2 phosphorylation and stability can be corrected using purified forms of EphrinA1-Fc. 3, 8 If our present findings can be extended to analogous situations in human, then adenoviral-based targeting of EphA2 could provide therapeutic benefit for these conditions. Consistent with this idea, recent studies have shown that EphA2 on these tumors can be targeted using Tumorigenicity of EphA2-overexpressing breast cancer cells LW Noblitt et al monoclonal antibodies 9, 31 and peptides. 15 The adenoviral approach offers the advantages over purified proteinbased approaches mainly due to the ability of adenoviral vectors to express high levels of EphrinA1 continuously and over longer periods of time. EphrinA1-Fc has the potential to engage and stimulate multiple different EphA (and some EphB) family members, which could be an issue for therapeutic specificity or toxicity. Yet, in this light, it is notable that no gross toxicities were observed in the xenograft modeling. Future studies will be necessary to evaluate the specificity and toxicity issues associated with adenoviral-based EphrinA1-Fc targeting. Since HAd-EphrinA1-Fc-infected cells efficiently secrete EphrinA1-Fc, it was anticipated that EphrinA1-Fc would have ''bystander effect.'' A significant inhibition in cell viability at a multiplicity of infection (m.o.i.) of 5 PFU per cell is an indirect evidence of bystander effect of EphrinA1-Fc.
We did detect differences in the efficiency of adenoviral delivery of EphrinA1-Fc and EphrinA1-Sc. The levels of EphrinA1-Fc expression and secretion in HAd-EphrinA1-Fc-infected cells were considerably higher than comparable studies with EphrinA1-Sc. These differences directly related to the relative efficacy of either construct in vitro, which is consistent with the specificity of this system. We did not attempt to determine the reason for differences in their levels of expression and secretion.
The fact that HAd-EphrinA1-Fc treatment was sufficient to inhibit established tumors, which is consistent with a recent report where targeted stimulation of EphA2 was sufficient in inhibiting tumorigenic potential. 9 It is particularly notable that we were able to achieve a powerful antitumor response with a single intratumoral inoculation with 1 Â 10 9 PFU of HAd-EphrinA1-Fc, albeit this was not sufficient to achieve tumor shrinkage. HAd vectors expressing cytokine, chemokine or costimulatory molecules, 16, 32, 33 interferon-inducing protein, p202 34 or inoculation with vector expressing thymidine kinase followed by systemic administration of ganciclovir 35 have been tested in breast cancer therapeutics with encouraging results. These approaches could be combined with EphA2-targeting to augment the therapeutic effect.
We did not monitor EphrinA1-Fc expression in mice following intratumoral inoculation with HAd-EphrinA1-Fc, therefore, the duration of EphrinA1-Fc expression was not known. In addition, whether the cells that were killed were infected with HAd-EphrinA1-Fc and the exact mechanism of cell killing require further investigation. However, our preliminary results suggest that there was increased expression of caspase 3 in breast cancer cells infected with HAd-EphrinA1-Fc, whereas bax expression remained unchanged (Noblitt and Mittal, unpublished data). It will be worthwhile to determine the status of other cellular proteins, such as low molecular weight phosphatase (LMW-PPT), 36 fibronectin, integrins, Src homology 2-containing phosphotyrosine phosphatase (SHP2), and FAK in response to HAd-EphrinA1-Fc infection in breast cancer cells. 
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Materials and methods
Cell culture and viruses
293 cells, HAd5 E1-transformed human embryonic kidney cells that support E1-deleted HAd replication, 37 were used primarily to grow recombinant E1-deleted HAd vectors. 293Cre cells (a gift from Merck, Inc., Whitehouse Station, NJ) not only support replication of E1-deleted HAd but also produce Cre-recombinase, 38 which catalyzes sitespecific homologous recombination in the presence of loxP sites. 27 The MT1A2 cell line was derived from polyoma virus middle T antigen (PyMidT)-induced mammary adenocarcinoma in transgenic mice. 32 This cell line was kindly provided by Dr William Muller, (Department of Biology, McMaster University, Hamilton, Ontario, Canada). 293, 293Cre, MT1A2, MDBK (Madin Darby Bovine Kidney cell line), and MDA-MB-231 (aggressive human breast cancer cell line) were grown as monolayer cultures in Eagle's minimum essential medium (MEM) (Gibco BRL, Gaithersburg, MD) supplemented with 5-10% reconstituted fetal bovine serum (FetalClone III; Hyclone, Logan, UT), 50 mg/ml gentamicin sulfate (Fisher Scientific, Pittsburgh, PA) and 50 mg/ml amphotericin B (Fisher Scientific). MCF-10A (nontransformed human breast epithelial cell line) cells were grown as monolayer cultures in MEM supplemented with 5% FetalClone III, 50 mg/ml gentamicin sulfate, 50 mg/ml amphotericin B, 10 mg/ml insulin (Sigma-Aldrich, Inc., St. Louis, MO), 50 mg/ml epidermal growth factor (Upstate Biotechnology, Lake Placid, NY) and 0.50 mg/ml hydrocortisone (Sigma-Aldrich). HAd5 vectors were grown in 293 cells and virus-infected cell pellets were used for preparation of virus stocks. For in vivo studies, purified virus preparations generated by cesium chloride-density gradient centrifugation. 39 Virus stocks and purified virus preparations were titrated in 293 cells by plaque assay.
Antibodies
The EphA2-specific monoclonal antibody (D7) was generated by Dr MS Kinch et al 40 and anti-EphrinA1 polyclonal antibody was purchased from Santa Cruz Biotechnology, (Santa Cruz, CA). An antibody specific for P-Tyr was acquired from Upstate Biological, Inc. (Waltham, MA) and b-catenin-specific, and E-cadherin-specific antibodies were obtained from Transduction Laboratories, (San Diego, CA). FITC-labeled antibodies: goat-anti-mouse-FITC and goat-anti-rabbit-FITC were procured from Southern Biotechnology (Birmingham, AL) and SigmaAldrich, respectively. HRP-conjugated antibodies: goat anti-mouse-HRP and goat anti-rabbit-HRP were from Bio Rad (Hercules, CA), whereas, a rabbit anti-mouse antibody was acquired from Chemicon (Temecula, CA).
Construction of E1 shuttle plasmids containing EphrinA1-Fc or EphrinA1-Sc and generation of HAd5 vectors
Restriction endonucleases, T4 DNA ligase, T4 polymerase, and their appropriate buffers were purchased from New England Biolabs (Beverly, MA). Calf intestine alkaline phosphatase and its appropriate buffer were obtained from Life Technologies, Inc. (Gaithersburg, MD). Plasmid DNA were purified using Qiagen Plasmid Maxi Kit (Qiagen Inc., Valencia, CA) following the manufacturer's protocol.
A 2.8 kb NruI and XbaI fragment containing the EphrinA1-Fc gene along with the cytomegalovirus (CMV) immediate early promoter was excised from pCDNA3-EphrinA1-Fc, pCDNA3 containing the EphrinA1 attached with Fc portion of IgG 1 (kindly provided by Dr BC Wang, Case Western Reserve University, Cleveland, OH). In order to obtain the EphrinA1-Sc (EphrinA1 without the transmembrane anchor and Fc portion of IgG 1 ) construct along with the CMV promoter, pCDNA3-EphrinA1-Fc was digested with NruI and BamH1 and a 1.2 kb fragment was isolated.
For generation of HAd5 vectors, the Cre recombinasemediated site-specific recombination system was used. 27 To generate HAd5 E1 shuttle plasmids containing EphrinA1-Fc (2.8 kb NruI-BamH1fragment), or EphrinA1-Sc (1.2 kb NruI-BamH1fragment), these DNA fragments were inserted at an appropriate site in the shuttle vector pDC316 (plasmid containing the left end of HAd5 (4 kb) with 3.1 kb E1 deletion, a loxp site for sitespecific recombination in the presence of Cre recombinase, and an intact packaging signal (C)) 27 to produce pDC316-EphrinA1-Fc and pDC316-EphrinA1-Sc, respectively. 293Cre cells were cotransfected with pDC316-EphrinA1-Fc or pDC316-EphrinA1-Sc and pBHGloxDE1,3Cre (plasmid containing almost entire HAd5 genome except the C, E1 and E3 deletions, and the addition of a loxp site for site-specific recombination) using the calcium-phosphate technique 41 to generate HAd-EphrinA1-Fc and HAd-EphrinA1-Sc, respectively by Cre recombinase-mediated site-specific recombination. The pDC316 and pBHGloxDE1,3Cre were obtained from Microbix, Inc. (Toronto, Ontario, Canada). Similarly, a vector having E1 and E3 deletions (HAd-DE1E3) was also constructed. HAd5 vectors were plaque purified in 293 cells.
Northern blot analysis
Total cellular RNA was isolated 24 hours postinfection using TRI reagent (Sigma-Aldrich) according to the manufacturer's protocol. Approximately 10 mg RNA was electrophoresed through 1.5% agarose-formaldehyde gel and transferred to a Zeta-probe membrane (BioRad Laboratories) by capillary transfer. 42 The membrane was incubated at 801C for 1 hour and prehybridized at 421C for 2 hours. Subsequently, the membrane was hybridized overnight at 421C with an EphrinA1-specific probe labeled with [a 32 P]-dCTP (Amersham Biosciences Corp., Piscataway, NJ) using random labeling kit (Invitrogen, Carlsbad, CA). The membrane was washed, exposed with a Phosphor Imager screen, scanned by Cyclone storage phosphor system and analyzed with OptiQuant image analysis software (Packard Instrument Company, Meriden, CT).
Western blot analysis
Cell lysates were fractionated on 10-12% SDS-polyacrylamide gels and transferred to nitrocellulose membranes (BioRad) by electrophoresis as described elsewhere. 42 To avoid non-specific binding, membranes were blocked with phosphate-buffered saline (PBS), pH 7.2 containing 0.05% Tween 20 and 5% dry skimmed milk. For detecting phosphorylation of immunoprecipitated EphA2, membranes were blocked using 2% cold fish gelatin and 0.1% bovine serum albumin instead of dry skim milk. Membranes were probed with one of the following primary antibodies, specific for: D7 (EphA2), 4G10 (P-Tyr), E-cadherin or EphrinA1. After extensive washing, the membranes were then probed with either goat anti-mouse IgG antibody-conjugated with HRP or goat anti-rabbit IgG-HRP as appropriate. For detection of EphrinA1-Fc, a goat anti-human IgG antibody-HRP was used as a primary antibody. The membranes were soaked in a 1:1 ratio of Super Signal West Pico Stable Peroxide Solution: Super Signal West Pico Luminol/ Enhancer (Pierce Co., Rockland, IL) for chemiluminescence and emitted light was captured by autoradiography (Kodak X-OMAT; Kodak, Rochester, NY) or enhanced chemiluminescence (Kodak Image Station; Kodak). Membranes were stripped and reprobed with a bcatenin-specific antibody to verify equal loading, and when feasible, membranes were cut into two pieces to avoid stripping.
Immunoprecipitation
Protein A sepharose (PAS) beads were treated with a rabbit anti-murine (RAM) IgG antibody to prepare RAM-attached to PAS (RAMPAS) as described. 16 Cell lysates and D7 antibody were added into microfuge tubes containing RAMPAS to allow specific binding of D7-EphA2 complexes to RAMPAS. Beads were washed extensively to remove the unbound proteins of the cell lysate. Immunoprecipitated protein samples were loaded and fractionated by SDS-PAGE, transferred to a nitrocellulose membrane and Western blot analysis was performed as described above.
Soft agar assay
MDA-MB-231 or MCF-10A cell monolayers at approximately 80-90% confluency were infected with HAdEphrinA1-Sc, HAd-EphrinA1-Fc, or HAd-DE1E3 at an m.o.i. of 5 PFU/cell. Following 6 hours of infection, cells were harvested by trypsinization and resuspended in 2 Â MEM supplemented with 10% FetalClone III. Warmed 0.6% agarose in water was then added in a 1:1 ratio to 2 Â MEM containing cells and the mixture was poured onto 0.3% agarose cushions in six-well dishes. The agarose was allowed to solidify at room temperature followed by incubation at 371C in a CO 2 incubator. Every third day, each dish alternatively received 250 ml/well of 1 Â MEM supplemented with 10% FetalClone III or 1 ml/well of 2 Â MEM and 0.6% agarose (1:1 ratio). At 12 days postinfection, colonies were assessed microscopically and defined as clusters of contiguous cells. The mean and standard deviation were calculated from data obtained from three independent samples. 
Statistical analysis
Statistical analyses of in vitro and in vivo data were performed using Student's t-distribution, defining significance as Po.05.
